{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["Storey CM"],"pubmed_abstract":["Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. Transforming growth factor-β (TGFβ) induces the expression of this plasma membrane protein specifically in aggressive and treatment resistant tumor cells derived from mesenchymal stem cells, with minimal expression observed in non-neoplastic tissues. We have developed a humanized monoclonal antibody, DUNP19, that specifically binds with high affinity to a phylogenetically conserved LRRC15 epitope and is rapidly internalized upon LRRC15 binding. In multiple subcutaneous and orthotopic tumor xenograft mouse models, Lutetium-177 labeled DUNP19 ([<sup>177</sup>Lu]Lu-DUNP19) enabled non-invasive imaging and molecularly precise radiotherapy to LRRC15-expressing cancer cells and murine"],"journal":["Signal transduction and targeted therapy"],"pagination":["319"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12480655"],"repository":["biostudies-literature"],"pubmed_title":["Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance."],"pmcid":["PMC12480655"],"pubmed_authors":["Thorek D","Trajkovic-Arsic M","Mao L","Altai M","Abou D","Subudhi SK","Cheng M","Ulmert D","Lamminmaki U","Ulmert E","Ridley A","Herrmann K","Damoiseaux R","Federman N","Zedan W","Park J","Siveke J","Storey CM","Zhu H","Czernin J","Hasson A","Graeber TG","Marks H","Yang X","Breuer L","Siddiqui BA","Luckerath K","Safi M","Yuen C","Geres S","Bentolila L"],"additional_accession":[]},"is_claimable":false,"name":"Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance.","description":"Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. Transforming growth factor-β (TGFβ) induces the expression of this plasma membrane protein specifically in aggressive and treatment resistant tumor cells derived from mesenchymal stem cells, with minimal expression observed in non-neoplastic tissues. We have developed a humanized monoclonal antibody, DUNP19, that specifically binds with high affinity to a phylogenetically conserved LRRC15 epitope and is rapidly internalized upon LRRC15 binding. In multiple subcutaneous and orthotopic tumor xenograft mouse models, Lutetium-177 labeled DUNP19 ([<sup>177</sup>Lu]Lu-DUNP19) enabled non-invasive imaging and molecularly precise radiotherapy to LRRC15-expressing cancer cells and murine","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T22:50:46.541Z","creation":"2026-05-02T03:11:45.625Z"},"accession":"S-EPMC12480655","cross_references":{"pubmed":["41022704"],"doi":["10.1038/s41392-025-02410-9"]}}